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7 ABSTRACT: The diastereoselective one-pot synthesis of hexahydrocyclopenta[b]pyrrole derivatives (bicycloprolines) has been
8 achieved by base-mediated reactions of (E)-tert-butyl 6-bromo-2-hexenoate with α-imino esters. The catalytic asymmetric version
9 of this process has been eﬃciently achieved using the CuI/(R)-DTBM-Segphos complex as a catalyst following a two-step 1,3-
10 dipolar cycloaddition/intramolecular alkylation sequence.
11 The pyrrolidine ring is present in a myriad of natural12 products and has been broadly used as a chemical core to
13 synthesize molecules with interesting pharmaceutical proper-
14 ties.1 In peptidomimetic chemistry α-quaternary proline
15 analogues have generated special interest due to their ability
16 to restrict the conformation and limit torsional angles of the
17 peptide backbone.2 Furthermore, proline derivatives have been
18 intensely used as ligands and organocatalysts in asymmetric
19 synthesis.3
20 Hexahydrocyclopenta[b]pyrrole derivatives (bicycloprolines)
21 are a signiﬁcant subclass of pyrrolidines, which represent an
22 important synthetic target due to their utility as amino acid
23 surrogates in biologically active peptides and their presence in
24 the structure of natural products.4 Representative examples
25 include hexahydrocyclopenta[b]pyrrole-6a-carboxylate, which
26 has been used as a building block in the synthesis of
27 peptidomimetics5 and natural products such as kopsihainanine
28 B6 and caldaphnidine R.7 Furthermore, Ramipril,8 a marketed
29 drug used to treat hypertension, presents a bicycloproline motif
f1 30 in its structure (Figure 1).
31 Despite the interest in these kinds of compounds, most of
32 the methods reported for their asymmetric preparation are
33 based on multistep sequences starting from enantioenriched
34 starting materials.9 Among the nonenantioselective proce-
35 dures10 for the synthesis of hexahydrocyclopenta[b]pyrrole
36 derivatives, the 1,3-dipolar cycloaddition of azomethine ylides
37 has emerged as one of the most eﬃcient. Thus, the groups of
38 Grigg11 and Overman12 have elegantly applied this method-
39 ology to the preparation of azabicyclooctanes and azatricyclo-
40 decanes. Both procedures were conducted under thermal
41 activation in reﬂuxing xylene, providing racemic products
s1 42 (Scheme 1).
43 One of the most direct methods for the preparation of
44 enantioenriched pyrrolidines is the catalytic asymmetric 1,3-
45dipolar cycloaddition of azomethine ylides with activated
46oleﬁns. Since the ﬁrst examples reported in 2002,13 numerous
47highly eﬃcient protocols using chiral metal catalysts as well as
48organocatalysts have been described. These new catalyst
49systems have allowed expanding the structural scope of the
50dipolarophiles and azomethine ylide precursors suitable for the
51intermolecular version of this reaction, providing enantiose-
52lective access to pyrrolidines with a variety of substitution
53patterns.14 In contrast, only a few examples of the intra-
54molecular version of this reaction have been reported.15
55Herein, in connection with our interest in metal-catalyzed
56asymmetric [3 + 2] cycloadditions of azomethine ylides,16 we
57report the ﬁrst procedure for the catalytic enantioselective
58synthesis of bicycloproline derivatives using a 1,3-dipolar
59cycloaddition/intramolecular alkylation sequence. This ap-
60proach aﬀords straightforward access to highly enantioenriched
61bicycloproline derivatives from readily available starting
62materials.
63We began our study by examining the reaction of N-
64benzylidene glycine methyl ester (1a) with (E)-tert-butyl 6-
65bromo-2-hexenoate17 (2) in the presence of a base such as
66NaH, conditions previously described for the preparation of α-
67alkylated iminoglycinates.18 We found that, using NaH in THF,
68the expected alkylated product was not observed, the bicyclic
69 t1product 4a being the only product detected (Table 1, entry 1).
70In a survey of a set of bases and solvents we obtained the best
71result using KOtBu in CH2Cl2 (Table 1, entry 4), which proved
72to be more eﬃcient than other strong bases such as LDA (entry
732), KHMDS, and LiHMDS (entries 5 and 6). Remarkably,
74under all the conditions studied only the endo adduct19 was
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75 detected in the 1H NMR of the crude mixtures. In contrast,
76 very low or no reactivity was observed using weaker bases, such
77 as DBU, Et3N, and Cs2CO3 (entries 7−10).
78 Since this approach constitutes a straightforward and
79 powerful diastereoselective one-pot procedure for the prepara-
80 tion of bicycloproline analogues, involving the formation of
81 three C−C bonds in a single operation, we undertook the study
s2 82 of the scope of the process. As summarized in Scheme 2, under
83 the optimized reaction conditions, the reaction took place with
84moderate to good yields (compounds 4b−j, 44−71% yield)
85and excellent diastereoselectivity (only the endo bicycloproline
86was isolated) with an array of aryl-substituted imino esters,
87regardless of the electronic and steric nature of the substituents,
88including the sterically demanding ortho-substituted aryl
89derivatives (products 4i,j).
90To gain some insight into the mechanism of this tandem
91reaction, a series of control experiments were carried out
92 s3(Scheme 3). First, we studied the feasibility of the cycloaddition
93between N-benzylidene glycine methyl ester (1a) with a β-
94substituted dipolarophile such as methyl crotonate (5). Under
95the base-mediated optimized conditions (1.1 equiv of KOtBu in
96CH2Cl2) the 1,3-dipolar cycloaddition aﬀorded a 2:1 mixture of
97endo/exo adducts 6 in 53% yield (Scheme 3, eq 1). On the
98other hand, no reaction was observed after treatment of imino
Figure 1. Selected compounds containing a bicycloproline motif.
Scheme 1. Synthesis of Bicycloprolines and Related
Derivatives by 1,3-Dipolar Cycloaddition of Azomethine
Ylides
Table 1. Optimization Experiments for the Model Reaction
entry base solvent conversion (%) yield (%)a
1 NaH THF >98 49
2 LDAb THF >98 43
3 KOtBu THF >98 57
4 KOtBu CH2Cl2 >98 71
5 KHMDSc CH2Cl2 70 60
6 LiHMDSd CH2Cl2 >98 16
7 4-DMAPe CH2Cl2 0
8 DBUf CH2Cl2 0
9 Et3N CH2Cl2 0
10 Cs2CO3 CH2Cl2 28
aIsolated yield. bLithium diisopropylamide. cPotassium bis-
(trimethylsilyl)amide. dLithium bis(trimethylsilyl)amide. e4-Dimethy-
laminopyridine. f1,8-Diazabicycloundec-7-ene.
Scheme 2. Scope of the Base-Mediated Process
Scheme 3. Related Studies of the Base-Mediated Reaction
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99 ester 1a with 1-bromohexane (7) in the presence of KOtBu (eq
100 2), showing that the intermolecular alkylation process is not
101 facile. Interestingly, the reaction of (E)-tert-butyl 7-bromo-2-
102 heptenoate (8; homologous substrate of the model bromoal-
103 kene 2) with the imino ester 1a in the presence of 1.1 equiv of
104 KOtBu led selectively to the pyrrolidine endo-9, the
105 corresponding azabicycle not being detected by NMR (Scheme
106 3, eq 3). All of these test reactions strongly suggest that the
107 direct synthesis of bicycloprolines 4 by base-promoted reaction
108 of α-imino esters 1 with the 6-bromohexenoate 2 occurs by a
109 starting intermolecular 1,3-dipolar cycloaddition followed by
110 intramolecular alkylation.
111 Next, we turned our attention toward the development of the
112 metal-mediated asymmetric version of the reaction in the
113 presence of a catalytic amount of the metal salt, chiral ligand,
114 and base. Taking into account the excellent enantioselectivities
115 described by several research groups,20 including ours,16 using
116 the chiral biphenyl DTBM-Segphos ligand, we focused our
117 attention on this ligand under silver- and copper-catalyzed
118 reaction conditions in the presence of a catalytic amount of
t2 119 KOtBu (Table 2). In agreement with the typically highly exo
120 diastereoselective behavior of this very bulky ligand in the 1,3-
121 dipolar cycloaddition with α,β-unsaturated esters,20b,16e the
122 reaction catalyzed by AgOAc provided the expected pyrrolidine
123 3a with high exo selectivity, albeit with moderate enantiose-
124 lectivity regardless of the solvent (entries 1−3, 51−73% ee). A
125 similar outcome was obtained using KHMDS instead of KOtBu
126 (entry 4). Pleasingly, further optimization of the reaction
127 conditions revealed that the Cu-catalyzed process was much
128 more enantioselective. Thus, the use of CuI/(R)-DTBM-
129 Segphos as the catalyst system in CH2Cl2 aﬀorded excellent
130 levels of eﬃciency and stereoselectivity (93% yield for exo-3a,
131 95% ee, entry 5). This cycloaddition can be also performed
132 with a lower catalyst loading (5 mol %), albeit with a very
133 important drop in the reactivity (70% conversion after 5 days,
134 entry 6).
135 At this stage we next studied the subsequent ring closure by
136 intramolecular SN2 alkylation of exo-3a. After a survey of
137 reaction conditions, we found that the treatment of the isolated
s4 138 pyrrolidine exo-3a with KOtBu in CH2Cl2 gave rise to the
139 s4desired bicyclic product 4a in good yield (79%, Scheme 4),
140preserving the enantiopurity of the starting pyrrolidine.
141Since this straightforward 1,3-dipolar cycloaddition/alkyla-
142tion process worked eﬃciently, we next studied the scope of the
143procedure with regard to the substitution at the azomethine
144 t3ylide (Table 3). Thus, imino esters 1 with diﬀerent aryl groups
145were investigated. The cycloaddition step proceeded nicely to
146aﬀord the desired pyrrolidines exo-3b−k as the only detectable
147isomers with excellent yield and enantioselectivity regardless of
148the steric and electronic nature of the substituents (78−95%
149yield, 90−96% ee).21 Further intramolecular alkylation by
150reaction with KOtBu took place with reasonable yield (51−65%
151yield), providing the desired highly enantioenriched diester
152azabicycles exo-4. The relative conﬁguration of the adducts exo-
1533 was established by NOE studies,22 while the exo conﬁguration
154of products 4 was unequivocally established by an X-ray
155diﬀraction analysis of (±)-exo-4a.23 As exempliﬁed in the case
156of the bicycloproline exo-4d, the selective deprotection of the
157tert-butyl ester can be readily achieved by straightforward
158treatment with TFA (product exo-4d-CO2H, 75% yield).
159In conclusion, tert-butyl 6-bromo-2-hexenoate has been
160studied as a novel dipolarophile in the catalytic asymmetric
1611,3-dipolar cycloaddition of azomethine ylides. The reaction in
162the presence of a stoichiometric amount of base (KtBuO)
163provided selectively the endo bicycloprolines in high yield by
164means of a tandem 1,3-dipolar cycloaddition/alkylation process.
165The enantioselective version of this reaction was achieved using
166CuI/(R)-DTBM-Segphos as the catalyst system for the starting
167highly exo selective cycloaddition step. The further base-
168promoted intramolecular alkylation aﬀorded the corresponding
Table 2. Optimization Experiments for Catalytic Asymmetric 1,3-Dipolar Cycloaddition with (R)-DTBM-Segphos as Ligand
entry [M] base solvent endo/exoa yield (%)b ee (%)c
1 AgOAc KOtBu THF 8/92 94 54
2 AgOAc KOtBu CH2Cl2 <2/>98 89 73
3 AgOAc KOtBu toluene 14/86 90 51
4 AgOAc KHMDS CH2Cl2 27:/ 28 77
5 CuPF6
d KOtBu CH2Cl2 <2/>98 93 95
6e CuPF6
d KOtBu CH2Cl2 <2/>98 70
f n.d.g
aDetermined by 1H NMR from the crude reaction mixture. bIsolated yield of adducts 3a. cEnantiomeric excess of exo-3a determined by HPLC.
dCuPF6 = Cu(CH3CN)4PF6.
e5 mol % of catalyst. f70% conversion yield after 5 days of reaction. gNot determined.
Scheme 4. Intramolecular SN2 Alkylation of exo-3a
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169 substituted bicycloprolines with high enantiopurity (90−96%
170 ee).
171 ■ EXPERIMENTAL SECTION
172 General Procedures. All air- and moisture-sensitive manipulations
173 were carried out in anhydrous solvents and under a nitrogen
174 atmosphere. Dichloromethane, toluene, tetrahydrofuran, and acetoni-
175 trile were dried over the PureSolv MD puriﬁcation system. Reactions
176 were monitored by thin-layer chromatography carried out on 0.25 mm
177 silica gel plates (230−400 mesh). Flash column chromatography was
178 performed using silica gel (230−400 mesh). When it was required,
179 silica gel was deactivated with a stirred solution of triethylamine in
180 cyclohexane (10% v/v) overnight and then ﬁltered, washed with
181 cyclohexane, and evaporated under reduced pressure. NMR spectra
182 were recorded on 300 and 500 MHz spectrometers and calibrated
183 using residual undeuterated solvent (CDCl3) as the internal reference
184 (δH 7.26 ppm, δC 77.16 ppm). HRMS spectra were measured on a
185 TOF mass spectrometer with electrospray ionization (ESI) as the
186ionization source. α-Imino esters 1a−k were prepared by condensation
187of methyl glycinate hydrochloride and the corresponding aldehydes.16
188Due to their lability, all α-imino esters, once isolated, were
189immediately used in the 1,3-dipolar cycloaddition without further
190puriﬁcation.
191Typical Procedure for the Base Mediated Synthesis of
192Azabicycles: (2S*,3R*,3aR*,6aR*)-3-tert-Butyl 6a-Methyl 2-
193Phenyloctahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate
194(endo-4a). To a solution of α-imino ester 1a (42.7 mg, 0.241 mmol)
195and bromoalkene 2 (50 mg, 0.201 mmol) in dry dichloromethane (2.5
196mL) was added potassium tert-butoxide (241 μL of a 1 M solution in
197THF, 0.241 mmol) dropwise. After 24 h at room temperature the
198reaction mixture was quenched with methanol (0.3 mL) and the
199solvent evaporated under reduced pressure. The residue was puriﬁed
200by deactivated silica gel ﬂash chromatography (hexane/AcOEt 6/1) to
201aﬀord endo-4a (49.3 mg, 71%, yellow oil). Due to their relative lability,
202bicycloprolines endo-4, once isolated. were stored at −20 °C. 1H NMR
203(300 MHz, CDCl3): 7.30−7.28 (m, 4H), 7.23−7.18 (m, 1H), 4.56 (d,
204J = 6.3 Hz, 1H), 3.77 (s, 3H), 3.11 (t, J = 8.8 Hz, 1H), 2.90 (dd, J =
Table 3. Substrate Scope of the CuI-DTBM-Segphos-Catalyzed Cycloaddition/Alkylation Sequence
aIsolated yield after chromatographic puriﬁcation. bee determined by HPLC. cIsolated as ammonium triﬂuoroacetate.
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205 6.3, 1.9 Hz, 1H), 2.22−2.19 (m, 2H), 1.83−1.74 (m, 3H), 1.61−1.49
206 (m, 1H), 1.02 (s, 9H). 13C NMR (75 MHz, CDCl3): 176.8, 172.1,
207 138.6, 128.2, 127.1, 126.8, 80.6, 76.8, 64.2, 58.2, 53.7, 52.5, 41.0, 33.6,
208 27.7, 26.7. HRMS (EI-QTOF): calcd for C20H28NO4, 346.2013;
209 found, 346.2023 ([M + H]+, 100%).
210 ( 2S* , 3R* , 3aR* , 6aR* ) -3 - te r t -Buty l 6a -Methy l 2 - (4 -
211 (Methoxycarbonyl)phenyl)octahydrocyclopenta[b]pyrrole-3,6a-di-
212 carboxylate (endo-4b). Following the typical procedure, the reaction
213 of α-imino ester 1b (56.7 mg, 0.241 mmol), bromoalkene 2 (50 mg,
214 0.201 mmol), and potassium tert-butoxide (241 μL of a 1 M solution
215 in THF, 0.241 mmol) in dry dichloromethane (2.5 mL) aﬀorded endo-
216 4b (47.0 mg, 58%, yellow oil). 1H NMR (300 MHz, CDCl3): 7.98 (d,
217 J = 8.2 Hz, 2H), 7.40 (d, J = 8.2 Hz, 2H), 4.59 (d, J = 6.2 Hz, 1H),
218 3.90 (s, 3H), 3.78 (s, 3H), 3.14−3.09 (m, 1H), 2.94 (dd, J = 6.2, 1.5
219 Hz, 1H), 2.26−2.20 (m, 2H), 1.85−1.73 (m, 3H), 1.56−1.50 (m, 2H),
220 1.02 (s, 9H). 13C NMR (75 MHz, CDCl3): 176.6, 171.8, 167.0, 144.0,
221 129.6, 129.0, 126.9, 81.0, 76.8, 64.1, 58.0, 53.7, 52.6, 52.2, 41.0, 33.7,
222 27.8, 26.7. HRMS (EI-QTOF): calcd for C22H30NO6, 404.2068;
223 found, 404.2080 ([M + H]+, 86.5%).
224 ( 2S* , 3R* , 3aR* , 6aR* ) -3 - te r t -Buty l 6a -Methy l 2 - (4 -
225 (Triﬂuoromethyl)phenyl)octahydrocyclopenta[b]pyrrole-3,6a-dicar-
226 boxylate (endo-4c). Following the typical procedure, the reaction of
227 α-imino ester 1c (59.1 mg, 0.241 mmol), bromoalkene 2 (50 mg,
228 0.201 mmol), and potassium tert-butoxide (241 μL of a 1 M solution
229 in THF, 0.241 mmol) in dry dichloromethane (2.5 mL) aﬀorded endo-
230 4c (39.1 mg, 47%, yellow oil). 1H NMR (500 MHz, CDCl3): 7.57 (d, J
231 = 8.2 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 4.60 (d, J = 6.1 Hz, 1H), 3.78
232 (s, 3H), 3.12 (t, J = 8.0 Hz, 1H), 2.93 (d, J = 5.5 Hz, 1H), 2.27−2.21
233 (m, 2H), 1.75−1.71 (m, 3H), 1.65−1.49 (m, 1H), 1.02 (s, 9H). 13C
234 NMR (125 MHz, CDCl3): 176.6, 171.8, 142.9 (q, J = 1.3 Hz), 129.6
235 (q, J = 32.4 Hz), 127.3, 125.2 (q, J = 3.8 Hz), 124.3 (q, J = 271.8 Hz),
236 81.1, 76.8, 63.9, 56.0, 53.6, 52.6, 41.0, 33.6, 27.8, 26.7. 19F NMR (470
237 MHz, CDCl3): −62.50. HRMS (EI-QTOF): calcd for C21H27F3NO4,
238 414.1887; found, 414.1896 ([M + H]+, 100%)
239 (2S*,3R*,3aR*,6aR*)-3-tert-Butyl 6a-Methyl 2-(4-(Methylthio)-
240 phenyl)octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (endo-
241 4d). Following the typical procedure, the reaction of α-imino ester
242 1d (53.8 mg, 0.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol), and
243 potassium tert-butoxide (241 μL of a 1 M solution in THF, 0.241
244 mmol) in dry dichloromethane (2.5 mL) aﬀorded endo-4d (49.6 mg,
245 63%, yellow oil). 1H NMR (300 MHz, CDCl3): 7.22−7.18 (m, 4H),
246 4.51 (d, J = 6.2 Hz, 1H), 3.77 (s, 3H), 3.12−3.07 (m, 1H), 2.88 (dd, J
247 = 6.2, 1.5 Hz, 1H), 2.44 (s, 3H), 2.23−2.18 (m, 2H), 1.83−1.73 (m,
248 3H), 1.54−1.52 (m, 1H), 1.05 (s, 9H). 13C NMR (75 MHz, CDCl3):
249 176.7, 172.0, 137.1, 135.7, 127.3, 126.8, 80.8, 76.8, 63.8, 58.1, 53.6,
250 52.5, 41.0, 33.6, 27.7, 26.7, 16.3. HRMS (EI-QTOF): calcd for
251 C21H30NO4S, 392.1891; found, 392.1886 ([M + H]
+, 100%).
252 (2S*,3R*,3aR*,6aR*)-3-tert-Butyl 6a-Methyl 2-(p-Tolyl)-
253 octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (endo-4e). Fol-
254 lowing the typical procedure, the reaction of α-imino ester 1e (4.1 mg,
255 0.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol), and potassium
256 tert-butoxide (241 μL of a 1 M solution in THF, 0.241 mmol) in dry
257 dichloromethane (2.5 mL) aﬀorded endo-4e (51.3 mg, 71%, yellow
258 oil). 1H NMR (300 MHz, CDCl3): 7.18 (d, J = 8.0 Hz, 2H), 7.09 (d, J
259 = 8.0 Hz, 2H), 4.51 (d, J = 6.2 Hz, 1H), 3.76 (s, 3H), 3.10 (t, J = 8.0
260 Hz, 1H), 2.87 (dd, J = 6.2, 1.6 Hz, 1H), 2.29 (s, 3H), 2.21−2.18 (m,
261 2H), 1.83−1.76 (m, 3H), 1.61−1.48 (m, 1H), 1.04 (s, 9H). 13C NMR
262 (75 MHz, CDCl3): 176.8, 172.2, 136.7, 135.4, 128.8, 126.6, 80.6, 76.8,
263 64.0, 58.3, 53.6, 52.5, 41.1, 33.6, 27.7, 26.7, 21.1. HRMS (EI-QTOF):
264 calcd for C21H30NO4, 360.2170; found, 360.2158 ([M + H]
+, 100%).
265 (2S*,3R*,3aR*,6aR*)-3-tert-Butyl 6a-methyl 2-(m-Tolyl)-
266 octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (endo-4f). Fol-
267 lowing the typical procedure, the reaction of α-imino ester 1f (4.1 mg,
268 0.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol), and potassium
269 tert-butoxide (241 μL of a 1 M solution in THF, 0.241 mmol) in dry
270 dichloromethane (2.5 mL) aﬀorded endo-4f (46.2 mg, 64%, yellow
271 oil). 1H NMR (300 MHz, CDCl3): 7.20−7.08 (m, 3H), 7.04−7.01 (m,
272 2H), 4.53 (d, J = 6.2 Hz, 1H), 3.78 (s, 3H), 3.09 (t, J = 7.4 Hz, 1H),
273 2.88 (dd, J = 6.2, 1.5 Hz, 1H), 2.31 (s, 3H), 2.22−2.15 (m, 2H), 1.84−
274 1.71 (m, 3H), 1.54−1.51 (m, 1H), 1.04 (s, 9H). 13C NMR (75 MHz,
275 CDCl3): 176.8, 172.2, 138.3, 137.8, 128.1, 127.8, 127.4, 123.9, 80.6,
27676.8, 64.1, 58.1, 53.7, 52.5, 41.0, 33.6, 27.8, 26.7, 21.5. HRMS (EI-
277QTOF): calcd for C21H30NO4, 360.2170; found, 360.2180 ([M + H]
+,
278100%).
279( 2S* , 3R* , 3aR* , 6aR* ) -3 - te r t -Buty l 6a -Methy l 2 - (3 -
280Methoxyphenyl)octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate
281(endo-4g). Following the typical procedure, the reaction of α-imino
282ester 1g (49.9 mg, 0.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol),
283and potassium tert-butoxide (241 μL of a 1 M solution in THF, 0.241
284mmol) in dry dichloromethane (2.5 mL) aﬀorded endo-4g (38.5 mg,
28563%, yellow oil). 1H NMR (300 MHz, CDCl3): 7.23−7.18 (m, 1H),
2866.91−6.88 (m, 2H), 6.78 (dd, J = 8.0, 2.2 Hz, 1H), 4.58 (d, J = 6.3 Hz,
2871H), 3.79 (s, 3H), 3.78 (s, 3H), 3.16−3.10 (m, 1H), 2.92 (dd, J = 6.3,
2882.0 Hz, 1H), 2.23−2.17 (m, 2H), 1.86−1.80 (m, 3H), 1.57−1.51 (m,
2891H), 1.07 (s, 9H). 13C NMR (75 MHz, CDCl3): 176.5, 172.0, 159.7,
290140.0, 129.3, 119.1, 113.1, 112.4, 80.8, 76.9, 64.1, 57.9, 55.4, 53.5, 52.6,
29140.8, 33.7, 27.7, 26.7. HRMS (EI-QTOF): calcd for C21H30NO5,
292376.2119; found, 376.2107 ([M + H]+, 100%).
293(2S*,3R*,3aR*,6aR*)-3-tert-Butyl 6a-Methyl 2-(Naphthalen-2-yl)-
294octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (endo-4h). Fol-
295lowing the typical procedure, the reaction of α-imino ester 1h (54.8
296mg, 0.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol), and
297potassium tert-butoxide (241 μL of a 1 M solution in THF, 0.241
298mmol) in dry dichloromethane (2.5 mL) aﬀorded endo-4h (35.0 mg,
29944%, yellow oil). 1H NMR (300 MHz, CDCl3): 7.80−7.80 (m, 4H),
3007.50−7.40 (m, 3H), 4.75 (d, J = 6.1 Hz, 1H), 3.80 (s, 3H), 3.19−3.14
301(m, 1H), 3.02 (d, J = 6.2 Hz, 1H), 2.30−2.20 (m, 2H), 1.88−1.80 (m,
3023H), 1.61−1.55 (m, 1H), 0.92 (s, 9H). 13C NMR (75 MHz, CDCl3):
303176.8, 172.1, 136.0, 133.4, 132.7, 128.0, 127.7, 127.6, 126.2, 125.8,
304125.7, 124.9, 80.8, 76.9, 64.3, 58.1, 53.8, 52.6, 41.1, 33.7, 27.7, 26.8.
305HRMS (EI-QTOF): calcd for C24H29NO4Na, 418.1989; found,
306418.2003 ([M + Na]+, 81.1%).
307(2S*,3R*,3aR*,6aR*)-3-tert-Butyl 6a-Methyl 2-(o-Tolyl)-
308octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (endo-4i). Fol-
309lowing the typical procedure, the reaction of α-imino ester 1i (4.1 mg,
3100.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol), and potassium
311tert-butoxide (241 μL of a 1 M solution in THF, 0.241 mmol) in dry
312dichloromethane (2.5 mL) aﬀorded endo-4i (42.6 mg, 59%, yellow
313oil). 1H NMR (300 MHz, CDCl3): 7.32−7.30 (m, 1H), 7.16−7.13 (m,
3143H), 4.64 (d, J = 6.4 Hz, 1H), 3.80 (s, 3H), 3.14 (t, J = 7.8 Hz, 1H),
3152.98 (d, J = 6.4 Hz, 1H), 2.36 (s, 3H), 2.29−2.18 (m, 2H), 1.86−1.72
316(m, 3H), 1.51−1.57 (m, 1H), 0.99 (s, 9H). 13C NMR (75 MHz,
317CDCl3): 176.8, 171.9, 136.0, 135.9, 130.1, 127.2, 125.9, 125.2, 80.5,
31876.0, 61.7, 56.0, 53.5, 52.5, 40.9, 33.8, 27.7, 26.8, 19.9. HRMS (EI-





323lowing the typical procedure, the reaction of α-imino ester 1j (54.8
324mg, 0.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol), and
325potassium tert-butoxide (241 μL of a 1 M solution in THF, 0.241
326mmol) in dry dichloromethane (2.5 mL) aﬀorded endo-4j (44.5 mg,
32756%, yellow oil). 1H NMR (300 MHz, CDCl3): 7.99 (d, J = 8.2 Hz,
3281H), 7.85 (d, J = 7.7 Hz, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.55−7.39 (m,
3294H), 5.26 (d, J = 6.2 Hz, 1H), 3.80 (s, 3H), 3.20−3.24 (m, 2H), 2.33−
3303.21 (m, 2H), 1.98−1.87 (m, 3H), 1.84−1.70 (m, 1H), 0.75 (s,
3319H).13C NMR (75 MHz, CDCl3): 176.8, 171.7, 133.7, 133.7, 131.6,
332128.9, 128.1, 126.1, 125.5, 125.3, 123.3, 122.7, 80.1, 75.9, 61.0, 57.4,
33353.3, 52.5, 41.0, 33.9, 27.4, 26.9. HRMS (EI-QTOF): calcd for
334C24H29NO4Na, 418.1989; found, 418.1982 ([M + Na]
+, 71.9%).
335(2S*,3R*,4R*,5S*)-4-tert-Butyl 2-Methyl 3-(4-Bromobutyl)-5-phe-
336nylpyrrolidine-2,4-dicarboxylate (endo-9). Following the typical
337procedure, the reaction of α-imino ester 1a (54.8 mg, 0.241 mmol),
338bromoalkene 8 (50 mg, 0.201 mmol), and potassium tert-butoxide
339(241 μL of a 1 M solution in THF, 0.241 mmol) in dry
340dichloromethane (2.5 mL) aﬀorded endo-9 (55.2 mg, 52%, yellow
341oil). 1H NMR (300 MHz, CDCl3): 7.45−7.18 (m, 5H), 4.51 (d, J =
3428.0 Hz, 1H), 3.81 (s, 3H), 3.56 (d, J = 7.9 Hz, 1H), 3.42 (t, J = 6.7 Hz,
3432H), 3.04−2.89 (m, 2H), 2.67−2.53 (m, 1H), 1.96−1.82 (m, 2H),
3441.81−1.68 (m, 1H), 1.62−1.40 (m, 3H), 1.02 (s, 9H). 13C NMR (75
345MHz, CDCl3): 173.1, 171.8, 138.7, 128.1, 127.4, 127.1, 80.7, 66.3,
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346 64.6, 56.9, 52.3, 48.5, 33.5, 33.1, 32.5, 27.4, 26.3. MS (ESI-QTOF):
347 calcd for C21H31BrNO4, 440.1431; found, 440.1425 ([M + H]
+,
348 100%).
349 Typical Procedure for the Asymmetric [3 + 2] Cycloaddition:
350 (2R,3S,4S,5S)-4-tert-Butyl 2-Methyl 3-(3-Bromopropyl)-5-phe-
351 nylpyrrolidine-2,4-dicarboxylate (exo-3a). To a stirred suspen-
352 sion of (R)-DTBM-Segphos (26.0 mg, 0.022 mmol) and [Cu-
353 (MeCN)4]PF6 (7.5 mg, 0.020 mmol) in dry dichloromethane were
354 successively added α-imino ester 1a (42.7 mg, 0.241 mmol in 0.5 mL
355 of dry dichloromethane), potassium tert-butoxide (20 μL of a 1 M
356 solution in THF, 0.020 mmol), and bromoalkene 2 (50 mg, 0.201
357 mmol in 0.5 mL of dry dichloromethane), After 24 h at room
358 temperature the reaction mixture was ﬁltered over Celite and
359 evaporated under reduced pressure. The residue was puriﬁed by silica
360 gel ﬂash chromatography (hexane/AcOEt 5/1) to aﬀord exo-3a (79.1
361 mg, 93%, yellow oil). All of the 3-bromopropyl-substituted
362 pyrrolidines 3 are relatively labile compounds. After isolation by
363 chromatography they were inmediatelly used in the next cyclization
364 step or stored at −20 °C. [α]D20 = −11.4 (c = 1.0, CHCl3), 95% ee.
365 HPLC: Daicel Chiralpak IC, hexane/isopropyl alcohol 95/5, ﬂow rate
366 0.7 mL min−1 (λ 211 nm), tR = 29.0 min ((2S,3R,4R,5R)-3a) and 37.3
367 min ((2R,3S,4S,5S)-3a). 1H NMR (300 MHz, CDCl3): 7.48−7.46 (m,
368 2H), 7.35−7.28 (m, 3H), 4.34−4.31 (m, 1H), 4.11−4.08 (m, 1H),
369 3.77 (s, 3H), 3.37 (t, J = 6.5 Hz, 2H), 2.78−2.74 (m, 1H), 2.64−2.58
370 (m, 1H), 2.51 (bs, 1H), 1.94−1.89 (m, 2H), 1.59−1.52 (m, 2H), 1.32
371 (s, 9H). 13C NMR (75 MHz, CDCl3): 174.0, 172.4, 140.9, 128.6,
372 127.9, 127.2, 81.2, 67.0, 63.1, 58.4, 52.0, 46.8, 33.3, 30.8, 28.9, 28.0.
373 HRMS (EI-QTOF): calcd for C20H29BrNO4, 426.1275; found,
374 426.1288 ([M + H]+, 100%).
375 (2R,3S,4S,5S)-4-tert-Butyl 2-Methyl 3-(3-Bromopropyl)-5-(4-
376 (methoxycarbonyl)phenyl)pyrrolidine-2,4-dicarboxylate (exo-3b).
377 Following the typical procedure, the reaction of α-imino ester 1b
378 (56.7 mg, 0.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol),
379 potassium tert-butoxide (20 μL of a 1 M solution in THF, 0.020
380 mmol), [Cu(MeCN)4]PF6 (7.5 mg, 0.020 mmol), and (R)-DTBM-
381 Segphos (26.0 mg, 0.022 mmol) in dry dichloromethane (2.5 mL)
382 aﬀorded exo-3b (75.8 mg, 78%, yellow oil). [α]D
20 = + 5.1 (c = 0.7,
383 CHCl3), 94% ee. HPLC: Daicel Chiralpak IB, hexane/isopropyl
384 alcohol 90/10, ﬂow rate 0.7 mL min−1 (λ 254 nm), tr = 16.4 min
385 ((2S,3R,4R,5R)-3b) and 19.9 min ((2R,3S,4S,5S)-3b). 1H NMR (300
386 MHz, CDCl3): 8.01 (d, J = 7.9 Hz, 2H), 7.57 (d, J = 7.9 Hz, 2H),
387 4.45−4.41 (m, 1H), 4.17−4.13 (m, 1H), 3.91 (s, 3H), 3.79 (s, 3H),
388 3.38 (t, J = 6.5 Hz, 2H), 2.79−2.77 (m, 1H), 2.64−2.62 (m, 1H),
389 1.95−1.86 (m, 2H), 1.59−1.55 (m, 2H), 1.34 (s, 9H). 13C NMR (75
390 MHz, CDCl3): 174.0, 172.2, 167.1, 146.9, 130.0, 129.8, 127.2, 81.6,
391 66.6, 63.2, 58.3, 52.2, 52.1, 47.0, 33.3, 30.9, 28.8, 28.1. HRMS (EI-
392 QTOF): calcd for C22H31BrNO6, 484.1330; found, 484.1332 ([M +
393 H]+, 100%).
394 (2R,3S,4S,5S)-4-tert-Butyl 2-Methyl 3-(3-Bromopropyl)-5-(4-
395 (methylthio)phenyl)pyrrolidine-2,4-dicarboxylate (exo-3d). Follow-
396 ing the typical procedure, the reaction of α-imino ester 1d (53.8 mg,
397 0.241 mmol), bromoalkene 2 (50 mg, 0.201 mmol), potassium tert-
398 butoxide (20 μL of a 1 M solution in THF, 0.020 mmol),
399 [Cu(MeCN)4]PF6 (7.5 mg, 0.020 mmol), and (R)-DTBM-Segphos
400 (26.0 mg, 0.022 mmol) in dry dichloromethane (2.5 mL) aﬀorded exo-
401 3d (83.3 mg, 95%, yellow oil). [α]D
20 = −0.4 (c = 10.2, CHCl3), 96%
402 ee. HPLC: Daicel Chiralpak IA, hexane/isopropyl alcohol 95/5, ﬂow
403 rate 0.7 mL min−1 (λ 211 nm), tr = 33.9 min ((2R,3S,4S,5S)-3d) and
404 40.1 min ((2S,3R,4R,5R)-3d). 1H NMR (300 MHz, CDCl3): 7.40 (d, J
405 = 7.9 Hz, 2H), 7.23 (d, J = 7.9 Hz, 2H), 4.33−4.31 (m, 1H), 4.11−
406 4.09 (m, 1H), 3.78 (s, 3H), 3.38 (t, J = 6.5 Hz, 2H), 2.78−2.77 (m,
407 1H), 2.62−2.59 (m, 2H), 2.47 (s, 3H), 1.95−1.89 (m, 2H), 1.56−1.54
408 (m, 2H), 1.34 (s, 9H). 13C NMR (75 MHz, CDCl3): 174.0, 172.3,
409 138.0, 137.9, 127.7, 126.9, 81.4, 66.6, 63.1, 58.2, 52.1, 46.9, 33.4, 30.9,
410 29.8, 28.1, 16.1. HRMS (EI-QTOF): calcd for C21H31BrNO4S,
411 472.1152; found, 472.1139 ([M + H]+, 93.3%).
412 (2R,3S,4S,5S)-4-tert-Butyl 2-Methyl 3-(3-Bromopropyl)-5-(4-
413 methylphenyl)pyrrolidine-2,4-dicarboxylate (exo-3e). Following the
414 typical procedure, the reaction of α-imino ester 1e (46.1 mg, 0.241
415 mmol), bromoalkene 2 (50 mg, 0.201 mmol), potassium tert-butoxide
416(20 μL of a 1 M solution in THF, 0.020 mmol), [Cu(MeCN)4]PF6
417(7.5 mg, 0.020 mmol), and (R)-DTBM-Segphos (26.0 mg, 0.022
418mmol) in dry dichloromethane (2.5 mL) aﬀorded exo-3e (82.3 mg,
41993%, yellow oil). [α]D
20 = −12.1 (c = 0.7, CHCl3), 92% ee. HPLC:
420Daicel Chiralpak IC, hexane/isopropyl alcohol 90/10, ﬂow rate 0.7 mL
421min−1 (λ 211 nm), tr = 24.5 min ((2S,3R,4R,5R)-3e) and 33.1 min
422((2R,3S,4S,5S)-3e). 1H NMR (300 MHz, CDCl3): 7.35 (d, J = 7.9 Hz,
4232H), 7.14 (d, J = 7.9 Hz, 2H), 4.33−4.30 (m, 1H), 4.12−4.09 (m,
4241H), 3.78 (s, 3H), 3.38 (t, J = 6.6 Hz, 2H), 2.81−2.75 (m, 1H), 2.63−
4252.56 (m, 2H), 2.33 (s, 3H), 1.97−1.88 (m, 2H), 1.62−1.48 (m, 2H),
4261.34 (s, 9H). 13C NMR (75 MHz, CDCl3): 173.9, 172.4, 137.7, 137.5,
427129.3, 127.0, 81.2, 66.8, 63.2, 58.3, 52.0, 46.9, 33.3, 30.8, 29.0, 28.1,
42821.2. HRMS (EI-QTOF): calcd for C21H31BrNO4, 440.1431; found,
429440.1428 ([M + H]+, 100%).
430(2R,3S,4S,5S)-4-tert-Butyl 2-Methyl 3-(3-Bromopropyl)-5-(3-
431methylphenyl)pyrrolidine-2,4-dicarboxylate (exo-3f). Following the
432typical procedure, the reaction of α-imino ester 1f (46.1 mg, 0.241
433mmol), bromoalkene 2 (50 mg, 0.201 mmol), potassium tert-butoxide
434(20 μL of a 1 M solution in THF, 0.020 mmol), [Cu(MeCN)4]PF6
435(7.5 mg, 0.020 mmol), and (R)-DTBM-Segphos (26.0 mg, 0.022
436mmol) in dry dichloromethane (2.5 mL) aﬀorded exo-3f (73.5 mg,
43783%, yellow oil). [α]D
20 = −5.4 (c = 1.0, CHCl3), 93% ee. HPLC:
438Daicel Chiralpak IC, hexane/isopropyl alcohol 90/10, ﬂow rate 0.7 mL
439min−1 (λ 211 nm), tr = 19.6 min ((2S,3R,4R,5R)-3f) and 27.3 min
440((2R,3S,4S,5S)-3f). 1H NMR (300 MHz, CDCl3): 7.26−7.18 (m, 3H),
4417.09−7.07 (m, 1H), 4.30 (d, J = 9.4 Hz, 1H), 4.10 (d, J = 8.5 Hz, 1H),
4423.77 (s, 3H), 3.37 (t, J = 6.6 Hz, 2H), 2.80−2.75 (m, 2H), 2.59 (t, J =
4439.4 Hz, 1H), 2.34 (s, 3H), 1.96−1.87 (m, 2H), 1.63−1.47 (m, 2H),
4441.34 (s, 9H). 13C NMR (75 MHz, CDCl3): 173.9, 172.5, 140.8, 138.2,
445128.9, 128.5, 127.9, 124.2, 81.3, 67.1, 63.3, 58.4, 52.1, 46.9, 33.4, 30.9,
44629.1, 28.1, 21.6. HRMS (EI-QTOF): calcd for C21H31BrNO4,
447440.1431; found, 440.1436 ([M + H]+, 99.4%).
448(2R,3S,4S,5S)-4-tert-Butyl 2-Methyl 3-(3-Bromopropyl)-5-(4-
449chlorophenyl)pyrrolidine-2,4-dicarboxylate (exo-3k). Following the
450typical procedure, the reaction of α-imino ester 1k (51.0 mg, 0.241
451mmol), bromoalkene 2 (50 mg, 0.201 mmol), potassium tert-butoxide
452(20 μL of a 1 M solution in THF, 0.020 mmol), [Cu(MeCN)4]PF6
453(7.5 mg, 0.020 mmol), and (R)-DTBM-Segphos (26.0 mg, 0.022
454mmol) in dry dichloromethane (2.5 mL) aﬀorded exo-3k (89.8 mg,
45578%, yellow oil). [α]D
20 = −4.9 (c = 10.0, CHCl3), 90% ee. HPLC:
456Daicel Chiralpak AS-H, hexane/isopropyl alcohol 98/2, ﬂow rate 0.7
457mL min−1 (λ 211 nm), tr = 22.9 min ((2S,3R,4R,5R)-3k) and 28.6 min
458((2R,3S,4S,5S)-3k). 1H NMR (300 MHz, CDCl3): 7.42 (d, J = 8.5 Hz,
4592H), 7.28 (d, J = 8.5 Hz, 2H), 4.33−4.31 (m, 1H), 4.09−4.07 (m,
4601H), 3.76 (s, 3H), 3.36 (t, J = 6.6 Hz, 2H), 2.78−2.72 (m, 1H), 2.61−
4612.54 (m, 1H), 2.34 (bs, 1H), 1.91−1.87 (m, 2H), 1.57−1.50 (m, 2H),
4621.33 (s, 9H). 13C NMR (75 MHz, CDCl3): 174.1, 172.2, 140.1, 133.5,
463128.7, 128.6, 81.4, 66.2, 63.0, 58.3, 52.0, 46.8, 33.3, 30.8, 28.8, 28.1.
464HRMS (EI-QTOF): calcd for C20H28BrClNO4, 460.0885; found,
465460.0897 ([M + H]+, 67.7%).
466(2R,3S,4S,5S)-4-tert-Butyl 2-Methyl 3-(3-Bromopropyl)-5-(2-
467methylphenyl)pyrrolidine-2,4-dicarboxylate (exo-3i). Following the
468typical procedure, the reaction of α-imino ester 1i (46.1 mg, 0.241
469mmol), bromoalkene 2 (50 mg, 0.201 mmol), potassium tert-butoxide
470(20 μL of a 1 M solution in THF, 0.020 mmol), [Cu(MeCN)4]PF6
471(7.5 mg, 0.020 mmol), and (R)-DTBM-Segphos (26.0 mg, 0.022
472mmol) in dry dichloromethane (2.5 mL) aﬀorded exo-3i (69.0 mg,
47378%, yellow oil). [α]D
20 = −18.1 (c = 12.7, CHCl3), 95% ee. HPLC:
474Daicel Chiralpak IC, hexane/isopropyl alcohol 90/10, ﬂow rate 0.7 mL
475min−1 (λ 211 nm), tr = 13.9 min ((2S,3R,4R,5R)-3i) and 19.8 min
476((2R,3S,4S,5S)-3i). 1H NMR (300 MHz, CDCl3): 7.66 (d, J = 7.6 Hz,
4771H), 7.23−7.10 (m, 3H), 4.62 (d, J = 8.9 Hz, 1H), 4.10 (d, J = 8.1 Hz,
4781H), 3.77 (s, 3H), 3.38 (t, J = 6.6 Hz, 2H), 2.82−2.70 (m, 3H), 2.36
479(s, 3H), 1.98−1.88 (m, 2H), 1.62−1.52 (m, 2H), 1.30 (s, 9H). 13C
480NMR (75 MHz, CDCl3): 174.1, 172.7, 138.6, 136.6, 130.4, 127.6,
481126.6, 126.4, 81.2, 63.4, 62.5, 57.5, 52.1, 47.1, 33.4, 30.9, 29.1, 28.0,
48219.6. HRMS (EI-QTOF): calcd for C21H31BrNO4, 440.1431; found,
483440.1444 ([M + H]+, 100%).
484Typical Procedure for the Cyclization of (3-Bromopropyl)-
485pyrrolidines: (2S,3S,3aS,6aS)-3-tert-Butyl 6a-Methyl 2-
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486 Phenyloctahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate
487 (exo-4a). To a stirred solution of pyrrolidine exo-3a (50 mg, 0.117
488 mmol) in dry dichloromethane (2.0 mL) was added potassium tert-
489 butoxide (129 μL of a 1 M solution in THF, 0.129 mmol) dropwise.
490 After 3 h at room temperature the reaction mixture was quenched with
491 methanol (0.3 mL) and evaporated under reduced pressure. The
492 residue was puriﬁed by deactivated silica gel ﬂash chromatography
493 (hexane/AcOEt 6/1) to aﬀord exo-4a (31.9 mg, 79%, yellow oil). Due
494 to their relative lability, bicycloprolines exo-4, once isolated, were
495 stored at −20 °C. [α]D20 = + 9.4 (c = 9.3, CHCl3), 96% ee. HPLC:
496 Daicel Chiralpak IC, hexane/isopropyl alcohol 95/5, ﬂow rate 0.5 mL
497 min−1 (λ 211 nm), tr = 11.1 min ((2R,3R,3aR,6aR)-4a) and 12.9 min
498 ((2S,3S,3aS,6aS)-4a). 1H NMR (300 MHz, CDCl3): 7.43 (d, J = 7.0
499 Hz, 2H), 7.27 (m, 3H), 4.20 (d, J = 10.0 Hz, 1H), 3.77 (s, 3H), 3.06
500 (t, J = 7.0 Hz, 1H), 2.36 (t, J = 9.4 Hz, 1H), 1.86 (m, 6H), 1.31 (s,
501 9H). 13C NMR (75 MHz, CDCl3): 178.4, 172.5, 141.6, 128.3, 127.7,
502 127.3, 80.8, 74.5, 65.7, 60.5, 52.8, 52.6, 40.5, 33.3, 28.2, 25.3. HRMS
503 (EI-QTOF): calcd for C20H28NO4, 346.2013; found, 346.2020 ([M +
504 H]+, 100%).
505 (2S,3S,3aS,6aS)-3-tert-Butyl 6a-Methyl 2-(4-(Methoxycarbonyl)-
506 phenyl)octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (exo-
507 4b). Following the typical procedure, the reaction of pyrrolidine exo-
508 3b (50 mg, 0.103 mmol) and potassium tert-butoxide (113 μL of a 1
509 M solution in THF, 0.113 mmol) in dry dichloromethane (2.0 mL)
510 aﬀorded exo-4b (22.9 mg, 55%, yellow oil). [α]D
20 = −17.9 (c = 4.7,
511 CHCl3), 93% ee. HPLC: Daicel Chiralpak IA, hexane/isopropyl
512 alcohol 98/2, ﬂow rate 0.7 mL min−1 (λ 254 nm), tr = 14.6 min
513 ((2R,3R,3aR,6aR)-4b) and 20.8 min ((2S,3S,3aS,6aS)-4b). 1H NMR
514 (300 MHz, CDCl3): 7.97 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.3 Hz, 2H),
515 4.27 (d, J = 9.8 Hz, 1H), 3.91 (s, 3H), 3.77 (s, 3H), 3.06 (m, 1H), 2.34
516 (t, J = 9.3 Hz, 1H), 1.87 (m, 6H), 1.31 (s, 9H). 13C NMR (75 MHz,
517 CDCl3): 178.2, 172.2, 167.2, 147.2, 129.7, 129.5, 127.3, 81.0, 74.6,
518 65.2, 60.5, 52.9, 52.6, 52.2, 40.5, 33.2, 28.2, 25.2. HRMS (EI-QTOF):
519 calcd for C22H30NO6, 404.2068; found, 404.2080 ([M + H]
+, 100%).
520 (2S,3S,3aS,6aS)-3-tert-Butyl 6a-Methyl 2-(4-(Methylthio)phenyl)-
521 octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (exo-4d). Fol-
522 lowing the typical procedure, the reaction of pyrrolidine exo-3d (50
523 mg, 0.106 mmol) and potassium tert-butoxide (116 μL of a 1 M
524 solution in THF, 0.116 mmol) in dry dichloromethane (2.0 mL)
525 aﬀorded exo-4d (21.2 mg, 51%, yellow oil). [α]D
20 = −1.7 (c = 1.1,
526 CHCl3), 96% ee. HPLC: Daicel Chiralpak IC, hexane/isopropyl
527 alcohol 95/5, ﬂow rate 0.7 mL min−1 (λ 254 nm), tr = 12.2 min
528 ((2R,3R,3aR,6aR)-4d) and 16.2 min ((2S,3S,3aS,6aS)-4d). 1H NMR
529 (300 MHz, CDCl3): 7.36 (d, J = 8.3 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H),
530 4.17 (d, J = 10.0 Hz, 1H), 3.76 (s, 3H), 3.03 (t, J = 7.3, 1H), 2.81 (bs,
531 1H), 2.46 (s, 3H), 2.31 (t, J = 9.4 Hz, 1H), 1.86 (m, 6H), 1.32 (s, 9H).
532
13C NMR (75 MHz, CDCl3): 178.3, 172.4, 128.8, 137.4, 127.8, 126.8,
533 80.8, 74.4, 65.1, 60.4, 52.8, 52.5, 40.9, 33.2, 28.2, 25.2, 16.3. HRMS
534 (EI-QTOF): calcd for C21H30NO4S, 392.1891; found, 392.1855 ([M +
535 H]+, 100%).
536 (2S,3S,3aS,6aS)-3-tert-Butyl 6a-Methyl 2-(4-Methylphenyl)-
537 octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (exo-4e). Fol-
538 lowing the typical procedure, the reaction of pyrrolidine exo-3e (50
539 mg, 0.114 mmol) and potassium tert-butoxide (125 μL of a 1 M
540 solution in THF, 0.125 mmol) in dry dichloromethane (2.0 mL)
541 aﬀorded exo-4e (26.6 mg, 65%, yellow oil). [α]D
20 = −17.6 (c = 10.7,
542 CHCl3), 93% ee. HPLC: Daicel Chiralpak IC, hexane/isopropyl
543 alcohol 95/5, ﬂow rate 0.7 mL min−1 (λ 211 nm), tr = 10.2 min
544 ((2R,3R,3aR,6aR)-4e) and 13.4 min ((2S,3S,3aS,6aS)-4e). 1H NMR
545 (300 MHz, CDCl3): 7.31 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H),
546 4.17 (d, J = 10.0 Hz, 1H), 3.76 (s, 3H), 3.04 (t, J = 7.4, 1H), 2.33 (m,
547 4H), 1.83 (m, 6H), 1.32 (s, 9H). 13C NMR (75 MHz, CDCl3): 178.4,
548 172.6, 138.6, 137.2, 128.9, 127.1, 80.7, 74.5, 65.4, 60.4, 52.9, 52.5, 40.5,
549 33.3, 28.2, 25.2, 21.3. HRMS (EI-QTOF): calcd for C21H30NO4,
550 360.2170; found, 360.2169 ([M + H]+, 100%).
551 (2S,3S,3aS,6aS)-3-tert-Butyl 6a-Methyl 2-(4-Chlorophenyl)-
552 octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (exo-4k). Fol-
553 lowing the typical procedure, the reaction of pyrrolidine exo-3k (50
554 mg, 0.109 mmol) and potassium tert-butoxide (125 μL of a 1 M
555 solution in THF, 0.119 mmol) in dry dichloromethane (2.0 mL)
556aﬀorded exo-4k (26.5 mg, 64%, yellow oil). [α]D
20 = −13.0 (c = 10.4,
557CHCl3), 90% ee. HPLC: Daicel Chiralpak IC, hexane/isopropyl
558alcohol 99/1, ﬂow rate 0.7 mL min−1 (λ 211 nm), tr = 13.3 min
559((2R,3R,3aR,6aR)-4k) and 18.1 min ((2S,3S,3aS,6aS)-4k). 1H NMR
560(300 MHz, CDCl3): 7.38 (d, J = 8.3 Hz, 2H), 7.26 (d, J = 8.3 Hz, 2H),
5614.18 (d, J = 10.0 Hz, 1H), 3.76 (s, 3H), 3.03 (t, J = 7.1, 1H), 2.28 (t, J
562= 9.4 Hz, 1H), 1.84 (m, 6H), 1.32 (s, 9H). 13C NMR (75 MHz,
563CDCl3): 178.2, 172.3, 140.3, 133.2, 128.6, 128.4, 81.0, 74.5, 64.8, 60.5,
56452.8, 52.6, 40.5, 33.2, 28.2, 25.2. HRMS (EI-QTOF): calcd for




568ing the typical procedure, the reaction of pyrrolidine exo-3f (50 mg,
5690.114 mmol) and potassium tert-butoxide (125 μL of a 1 M solution in
570THF, 0.125 mmol) in dry dichloromethane (2.0 mL) aﬀorded exo-4f
571(25.4 mg, 62%, yellow oil). [α]D
20 = −12.5 (c = 9.5, CHCl3), 92% ee.
572HPLC: Daicel Chiralpak IC, hexane/isopropyl alcohol 98/2, ﬂow rate
5730.7 mL min−1 (λ 211 nm), tr = 12.5 min ((2R,3R,3aR,6aR)-4f) and
57416.1 min ((2S,3S,3aS,6aS)-4f). 1H NMR (300 MHz, CDCl3): 7.19 (m,
5753H), 7.05 (d, J = 6.8 Hz, 1H), 4.16 (d, J = 10.1 Hz, 1H), 3.76 (s, 3H),
5763.05 (t, J = 7.2, 1H), 2.33 (m, 5H), 1.85 (m, 6H), 1.32 (s, 9H). 13C
577NMR (75 MHz, CDCl3): 178.4, 172.6, 141.5, 137.8, 128.4, 128.2,
578127.8, 124.3, 80.7, 74.5, 65.7, 60.4, 52.9, 52.5, 40.5, 33.2, 28.1, 25.2,
57921.6. HRMS (EI-QTOF): calcd for C21H30NO4, 360.2170; found,
580360.2161 ([M + H]+, 100%).
581(2S,3S,3aS,6aS)-3-tert-Butyl 6a-Methyl 2-(2-Methylphenyl)-
582octahydrocyclopenta[b]pyrrole-3,6a-dicarboxylate (exo-4i). Follow-
583ing the typical procedure, the reaction of pyrrolidine exo-3i (50 mg,
5840.114 mmol) and potassium tert-butoxide (125 μL of a 1 M solution in
585THF, 0.125 mmol) in dry dichloromethane (2.0 mL) aﬀorded exo-4i
586(24.6 mg, 60%, yellow oil). [α]D
20 = −9.9 (c = 7.4, CHCl3), 96% ee.
587HPLC: Daicel Chiralpak IC, hexane/isopropyl alcohol 98/2, ﬂow rate
5880.7 mL min−1 (λ 211 nm), tr = 9.8 min ((2R,3R,3aR,6aR)-4i) and 13.3
589min ((2S,3S,3aS,6aS)-4i). 1H NMR (300 MHz, CDCl3): 7.56 (d, J =
5907.1 Hz, 1H), 7.13 (m, 3H), 4.45 (d, J = 10.1 Hz, 1H), 3.78 (s, 3H),
5913.06 (t, J = 7.4, 1H), 2.79 (bs, 1H), 2.54 (t, J = 9.3 Hz, 1H), 2.39 (s,
5923H), 1.84 (m, 6H), 1.28 (s, 9H). 13C NMR (75 MHz, CDCl3): 178.4,
593172.7, 138.8, 136.6, 130.7, 127.3, 126.8, 126.1, 80.7, 74.5, 61.3, 59.1,
59453.0, 52.5, 40.2, 33.2, 28.1, 25.4, 19.6. HRMS (EI-QTOF): calcd for




5984d-CO2H). The azabicycle exo-4d (17.6 mg, 0.045 mmol) was
599dissolved in triﬂuoroacetic acid (1 mL), and the resulting solution was
600stirred at room temperature for 1 h. The acid was removed in vacuo to
601provide exo-4d-CO2H (13.2 mg, 87%, yellow oil). [α]D
20 = −15.8 (c =
60210.2, CHCl3).
1H NMR (300 MHz, CDCl3): 9.97 (bs), 7.33−7.30 (m,
6032H), 7.17−7.15 (m, 2H), 4.70 (d, J = 11.6 Hz, 1H), 3.92 (s, 3H),
6043.38−3.23 (m, 2H), 2.62−2.32 (m, 4H), 2.15−2.09 (m, 5H). 13C
605NMR (75 MHz, CDCl3): 173.1, 171.7, 142.8, 128.6, 126.3, 124.8,
60677.2, 77.0, 66.7, 54.9, 53.7, 52.3, 35.7, 31.7, 25.0, 15.0. HRMS (ESI-




611The Supporting Information is available free of charge on the
612ACS Publications website at DOI: 10.1021/acs.joc.6b01100.
613
1H and 13C NMR spectra for all new compounds, HPLC
614traces used to determine enantiomeric purity, and X-ray
615crystallographic data of compound (±) exo-4a (PDF)
616X-ray crystallographic data of (±) exo-4a(CIF)
617■ AUTHOR INFORMATION
618Corresponding Authors
619*E-mail for J.A.: javier.adrio@uam.es.
620*E-mail for J.C.C.: juancarlos.carretero@uam.es.
The Journal of Organic Chemistry Note
DOI: 10.1021/acs.joc.6b01100
J. Org. Chem. XXXX, XXX, XXX−XXX
G
621 Notes
622 The authors declare no competing ﬁnancial interest.
623 ■ ACKNOWLEDGMENTS
624 Financial support of this work by the Ministerio de Economiá y
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